Calendario›TRAW›ON 01910.Na

ON 01910.Na

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Ensayo de Traws Pharma, Inc. en Tumor solido.

Más ensayos de: Tumor sólido.

Fase

Fase 1

Estado

Completado

Participantes

10

previstos

Centros

2

Fin del objetivo primario

jul 2011

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en ene 2010.

Qué mide

Adverse Events and Laboratory Parameters (Throughout study) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroTreatment of cancer is often more effective when two or more drugs are used together. For example, when gemcitabine, an approved drug, and ON 01910.Na, a new investigational anti-cancer drug, are used together to treat cancer cells in laboratory animals, there is more inhibition of the growth of the cancer cells compared to either drug used by itself. These results offer promise that gemcitabine and ON 01910.Na could be used to treat cancer in patients. However, before studies that seek to find out if gemcitabine and ON 01910.Na is an effective combination in patients can be done, doctors must first know what is largest, safe dose of ON 01910.Na that can be used in combination with gemcitabine and what is the best regimen to use. This study is designed to answer that question.

Más ensayos de TRAW

Todos los de TRAW, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT01165905), actualizada en jun 2017.